复发/难治性 B 细胞淋巴瘤 CAR-T 细胞治疗后血小板和纤维蛋白原动态可能预测 ICANS 发生

CAR-T cell therapy is efficient in relapsed/refractory B-cell lymphoma; yet, cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) remain major and potentially life-threatening complications, which makes their prediction and prevention crucial. This international, retrospective study analyzed the predictive value of coagulation parameter dynamics for ICANS and CRS development in 265 B-cell lymphoma patients at two tertiary-care centers. Platelet counts, fibrinogen, PT, PTT, international normalized ratio, and D-dimer, were recorded daily from pre-lymphodepletion through 2 weeks post-infusion. ICANS occurred in 34% of patients, with high-grade events documented in 13%.

Patients with ICANS had significantly lower median platelet (67 vs. 123 10 3 / L) and fibrinogen (263 vs. 379 mg/dL) levels than those without ICANS. During high-grade ICANS days, fibrinogen and platelet levels were significantly reduced (p = 0. 003 and p = 1. 6 10 -14 , respectively).

In > 75% of high-grade ICANS cases, 1 day before its onset, platelet counts were < 100 10 9 /L (median decrease: 11. 6% versus 1. 6% on other days; p = 0. 001). Conversely, on the day preceding ICANS onset, higher fibrinogen concentrations were observed, with median values of 448 mg/dL in the ICANS group versus 376 mg/dL in the non-ICANS group (p = 0. 03).

These findings suggest that platelet and fibrinogen dynamics could be early indicators of ICANS development in lymphoma patients.